{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chimeric+antigen+receptor+%28CAR%29+T+cell+therapy&page=2",
    "query": {
      "intervention": "chimeric antigen receptor (CAR) T cell therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 345,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chimeric+antigen+receptor+%28CAR%29+T+cell+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chimeric+antigen+receptor+%28CAR%29+T+cell+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T14:37:36.139Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04789408",
      "title": "Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "KITE-222",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-19",
      "completion_date": "2024-05-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Tampa, Florida • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04789408"
    },
    {
      "nct_id": "NCT03792633",
      "title": "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "huCART19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "3 Months to 29 Years"
      },
      "enrollment_count": 106,
      "start_date": "2019-01-18",
      "completion_date": "2024-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03792633"
    },
    {
      "nct_id": "NCT04975555",
      "title": "Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Release Syndrome",
        "ICANS",
        "Lymphoma, Non-Hodgkin",
        "Multiple Myeloma",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-11-15",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04975555"
    },
    {
      "nct_id": "NCT05607420",
      "title": "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma (B-NHL)"
      ],
      "interventions": [
        {
          "name": "UCART20x22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CLLS52",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellectis S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-11-01",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05607420"
    },
    {
      "nct_id": "NCT06364423",
      "title": "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "B-Lymphocytic Leukemia, Chronic",
        "B-Cell Chronic Lymphocytic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma",
        "Leukemia, Acute Lymphoblastic",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous HuCD19 ( Anti-CD19)CAR T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 132,
      "start_date": "2024-09-03",
      "completion_date": "2030-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06364423"
    },
    {
      "nct_id": "NCT02439788",
      "title": "3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "GINAKIT Cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-08",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02439788"
    },
    {
      "nct_id": "NCT03873805",
      "title": "PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2019-08-20",
      "completion_date": "2027-03-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03873805"
    },
    {
      "nct_id": "NCT06561425",
      "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
        "Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell"
      ],
      "interventions": [
        {
          "name": "GLPG5101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Lakefront Biotherapeutics NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-09",
      "completion_date": "2026-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06561425"
    },
    {
      "nct_id": "NCT06298019",
      "title": "Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dermatomyositis"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "25 Years to 72 Years"
      },
      "enrollment_count": 21,
      "start_date": "2024-08-02",
      "completion_date": "2039-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Stanford, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06298019"
    },
    {
      "nct_id": "NCT04601831",
      "title": "'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Focal radiation therapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-12-23",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-10T14:37:36.139Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04601831"
    }
  ]
}